Sanofi will soon commence a Phase I/II trial with its vaccine candidate to start generating immunogenicity data.

Total company revenue fell from a peak of $19.3 billion in 2022 to $3.2 billion for the full year ended Dec. 31, 2024. For ...

We recently published a list of 10 Stocks To Trade Without Tariffs And Interest Rate Fears. In this article, we are going to ...

Recently, AIM announced a comprehensive deployment to integrate the DeepSeek large model, particularly in vaccine development ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...

A new study by Fikrig and other researchers, published Wednesday in Science Translational Medicine, uses a powerful ...

Is it time to average down on a Moderna holding or begin a new position? Let's look at the company's recent performance and ...

Population-based analyses of new vaccination programmes provide robust real-world evidence for post-licensure vaccine ...

Shares of vaccine-maker Moderna MRNA closed at $34.71 on Monday, close to their 52-week low of $29.25. Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft sales ...

the mRNA shingles vaccine and the mRNA RSV vaccine. In just one month, AIM has leveraged its independently innovated mRNA technology platform to deliver two major products, both of which have received ...

With AI support, AIM is expected to rapidly advance multiple key products, including the mRNA shingles vaccine, mRNA RSV vaccine, and mRNA influenza vaccine. Previously, the research report from Fosun ...